argenx to Buy Unnatural Products for $550M Upfront, Up to $1.15B Total
ARGX sits 35% above its 52-week low of $661.85.
Summary
argenx agreed to acquire Unnatural Products for $550 million upfront in cash plus up to $595 million in milestone payments, up to roughly $1.15 billion total, adding a macrocyclic peptide discovery platform to its immunology pipeline. The deal is expected to close by year-end.
Key Events · M&A and Partnerships · ARGX
-
argenx to Acquire Unnatural Products
Definitive agreement to buy all remaining shares of Unnatural Products, valuing the macrocyclic peptide discovery company at up to approximately $1.15 billion.
-
Deal Structure: $550M Upfront, $595M Milestones
$550 million in cash on hand at closing plus up to $595 million contingent on specified development and regulatory milestones.
-
Peptide Platform Adds Oral, Long-Acting Options
UNP's macrocyclic peptide engine pairs with argenx's antibody engineering, extending the pipeline toward oral and long-acting immunology medicines; argenx already held a minority stake after more than two years of collaboration.
-
Close Expected by Year-End
Both boards approved the transaction; closing is expected by the end of the year, subject to customary closing conditions. UNP will continue operating from Santa Cruz, California.
Analysis · ARGX · Life Sciences
argenx is paying $550 million in cash up front, plus up to $595 million contingent on development and regulatory milestones, to own Unnatural Products' macrocyclic peptide discovery engine outright — it already held a minority stake. Platform breadth is the strategic logic: peptides could yield oral and long-acting immunology medicines that complement argenx's antibody franchise, and the company keeps UNP's Santa Cruz team intact. Against a $57.5 billion market cap the upfront is a manageable bolt-on rather than a thesis-changing bet, and the cash comes from the balance sheet, so there is no dilution. Whether the platform produces clinical candidates is the real question, which is why most of the consideration sits behind milestones. Closing is expected by year-end, subject to customary conditions.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARGX was trading at $894.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57.5B. The 52-week trading range was $661.85 to $1,072.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.